Inhibition of Ccl2 and Ccl8 depletes MDMs and alleviates liver fibrosis in Tet2 ^ΔMye -CCl ₄ mice. (A and B) Effect of Bindarit inhibition on serum Ccl2 (A) and Ccl8 (B) levels in Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ littermates (n = 4 for each group). (C–E) IHC staining (C) and statistical analysis of Ccl2 (D) and Ccl8 (E) expression after Bindarit treatment in livers of Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ littermates (n = 4 for each group). Scale bar, 100 μm. (F and G) Picrosirius red staining (F) and statistical analysis (G) of collagen deposition in livers of Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ littermates (n = 4 for each group). Scale bar, 100 μm. (H–K) Effect of Bindarit on α-SMA and collagen I expression evaluated by western blot (H) and IHC staining (I, J, and K) (scale bar, 100 μm) in livers of Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ littermates (n = 4 for each group). (L and M) Changes in serum Col IV (M) and HA (N) in Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ littermates after PBS or Bindarit treatment (n = 5 for each group). (N) Changes in intrahepatic MDMs frequency after Bindarit treatment in Tet2^WT-CCl₄ and Tet2^ΔMye-CCl₄ littermates. Data are representative of at least two independent experiments with similar results (A–L). All data are shown as mean ± SD and were analyzed by two-way ANOVA with Sidak’s multiple comparison test (A, B, D, E, G, and J–N). ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns). Source data are available for this figure: SourceData F5.